Patent Claims

Amen. A1

1. Compounds of the formula I



I

in which

R^1, R^2 in each case independently of one another are H, A, OH, OA or Hal,

R^1 and R^2 together are also alkylene having 3-5 C atoms, $-O-CH_2-CH_2-$, $-CH_2-O-CH_2-$, $-O-CH_2-O-$ or $-O-CH_2-CH_2-O-$,

R^3, R^4 in each case independently of one another are H or A,

X is R^5, R^6 or R^7 monosubstituted by R^8,

R^5 is linear or branched alkylene having 1-10 C atoms, in which one or two CH_2 groups can be replaced by -CH=CH- groups, O, S or SO,

R^6 is cycloalkyl or cycloalkylalkylene having 5-12 C atoms,

R^7 is phenyl or phenylmethyl,

R^8 is COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$ or CN,

A is alkyl having 1 to 6 C atoms and

contd. A1

Hal is F, Cl, Br or I,

and their physiologically acceptable salts and solvates.

2. Compounds of the formula I according to Claim 1

(a) 5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid;
(b) 4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]benzoic acid;
(c) 4-[7-(3,4-methylene-dioxy-benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid;
(d) 5-[7-(benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid

and their physiologically acceptable salts and solvates.

3. Process for the preparation

of compounds of the formula I according to Claim 1 and their salts,

characterized in that

a) a compound of the formula II



II

contd. A1

in which

R^3, R^4 and X have the meanings indicated in Claim 1,

and L is Cl, Br, OH, SCH_3 or a reactive esterified OH group,

is reacted with a compound of the formula III



III

in which

R^1 and R^2 have the meanings indicated,

or

b) in a compound of the formula I, a radical X is converted into another radical X by, for example, hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

and/or a compound of the formula I is converted into one of its salts.

4. Process for the production of pharmaceutical preparations, characterized in that a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and solvates is brought into a suitable dose form together with at least one solid, liquid or semi-liquid vehicle or excipient.

contd. A1

5. Pharmaceutical preparation characterized in that it contains at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and solvates.

6. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts and solvates for the control of diseases of the cardiovascular system and for the treatment and/or ~~therapy of potency disorders.~~

Sub B1

7. Medicaments of the formula I according to Claim 1 and their physiologically acceptable salts and solvates as phosphodiesterase V inhibitors.

Amen. A2

8. Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the production of a medicament.

9. Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the production of a medicament for the control of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders.

add B1